CRISPR-enabled biosensing of cancer-associated DNA methylation in cell-free DNA: molecular architectures, molecular sampling constraints, and translational biosensor engineering
Oct 2026· Frontiers in Bioengineering and Biotechnology· Vol 14· 0 citations· 128 references
Medicine
TL;DR
No native-state Cas methylation assay identified in this review has established clinically usable diagnostic performance, and reported analytical limits of detection and methylation-fraction discrimination cannot be extrapolated to clinical sensitivity without accounting for input, recovery, fragmentation, background, and decision thresholds.
Abstract
DNA methylation in circulating cell-free DNA (cfDNA) provides cancer-associated and tissue-of-origin information complementary to mutation-based liquid biopsy. Clustered regularly interspaced short palindromic repeats (CRISPR)-based sensing is challenging because 5-methylcytosine (5 mC) generally preserves Watson-Crick base pairing and is not inherently resolved by sequence-programmed CRISPR-associated (Cas) proteins. This targeted narrative review examines how methylated and unmethylated molecules are distinguished and converted into Cas-readable outputs under fragmented, low-input cfDNA conditions. We organize the literature into four discrimination routes comprising sequence conversion, enzymatic gating, affinity-assisted recognition, and native-state Cas modulation. Engineered molecular transduction is considered separately as a downstream enabling layer. We compare readouts in terms of quantitative fidelity and integration requirements. Sequence-conversion and enzymatic-gating systems have the broadest analytical evidence among the identified studies, largely from in vitro experiments. Direct affinity-assisted 5 mC-to-Cas sensing remains sparsely studied, and evidence for native-state sensing in patient-derived cfDNA is limited to exploratory observational comparisons. No native-state Cas methylation assay identified in this review has established clinically usable diagnostic performance. Reported analytical limits of detection and methylation-fraction discrimination cannot be extrapolated to clinical sensitivity without accounting for input, recovery, fragmentation, background, and decision thresholds. Translation requires validated biomarkers, fragment-matched calibration, orthogonal reference testing, reproducible device integration, and independent evaluation of locked assays in intended-use populations.
DACAR provides a unified, programmable framework for precise molecular-level control of Cas13a, advancing its potential in diagnostics and molecular logic.
Chang-Qing Wan, Wen-Zheng Liu, Shu-Tao Pan et al.· Biosensors & bioelectronics· 0 citations
PIWI-interacting RNA (piRNA) as a type of small non-coding RNA holds great promise for managing disease occurrence and progression. Herein, we construct a ligation-assisted DNA strand displacement strategy for enhanced CRISPR/Cas14 cleavage, which provides remarkable SERS and electrochemical responses to indicate trace...
Xiao-Qiang Li, Zhen-Zhen Guo, Wei-Feng Ye et al.· Biosensors & bioelectronics· 0 citations
DNA methylation is a fundamental epigenetic modification that regulates gene expression, cellular identity, and disease-associated regulatory programs. However, high-throughput single-cell DNA methylation technologies have been limited by DNA degradation, low CpG recovery, and the poor scalability of bisulfite-based me...
Gao-Jie Li, Yang Yang, Zhuo-Ran Li et al.· Science Advances· 0 citations
A bisulfite-free and PCR-free electrochemical nanochannel biosensor that modulates nanoconfined space charge to directly translate discrete epigenetic marks into measurable ion flux is reported, demonstrating great translational potential for precise epigenetic liquid biopsy.
Kai Hu, Zi-Meng Zhang, Bing-Heng Li et al.· Biosensors & bioelectronics· 0 citations
Alzheimer's disease (AD) is associated with pathological changes that can occur years before the onset of clinical symptoms, highlighting the importance of sensitive biomarker detection for early diagnosis. Here, we developed a fluorescence biosensing platform based on CRISPR/Cas13a-assisted hyperbranched rolling circl...
Juan Song, Hui-Xin Yue, Chuan-Song Zhang et al.· Talanta: The International J...· 0 citations
Adoption of CRISPR epigenome editing is approaching clinical translation, but adoption will depend on rigorous causal target validation, standardized reporting, multilayer specificity assays, controllable delivery and evidence that corrected expression remains within a safe physiological window.
E. K. Oladipo, Victoria Oluwayemisi Adubiaran, A. Iyiola et al.· Clinical and Translational D...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.